Rezolute Inc. (RZLT), a late-stage company focused on ultra-rare diseases, announced positive interim results from its ongoing Phase 3 upLIFT study of Ersodetug in patients with tumor-related hyperinsulinism (HI).
Rezolute, Inc. (RZLT) will present new findings from its pivotal Phase 3 sunRIZE study evaluating Ersodetug, a monoclonal antibody designed to treat hypoglycemia caused by congenital hyperinsulinism (HI), at the Pediatric Endocrine Society (PES) Annual Meeting on May 1, 2026.
Rezolute, Inc. (RZLT) Wednesday reported that its Phase 3 sunRIZE study in failed to meet its primary endpoint of reducing hypoglycemia events or the key secondary endpoint of time spent in hypoglycemia. However, in line with its Phase 2 RIZE study results, the drug candidate showed pharmacologic activity.
Rezolute, Inc. (RZLT), a rare disease company, announced Thursday topline results from its Phase 3 sunRIZE study evaluating ersodetug in patients with congenital hyperinsulinism (HI). The study did not meet its primary endpoint, which assessed change in the average weekly hypoglycemia events by self-monitored...
A disease that affects less than 200,000 people in the United States at any given time is classified as a rare disease. There are over 6,800 rare diseases, according to the National Human Genome Research Institute. Approximately 80% of rare diseases are believed to have a genetic origin.
August 13, 2026 05:33 ET The World Health Organization’s cancer research agency, the International Agency for Research on Cancer (IARC), has classified three widely used medicines as carcinogenic to humans.